What the Mounjaro trial evidence actually shows

The biggest myth: the trial results are the results you should expect

If you've read anything about Mounjaro recently, you've probably seen the 20% figure. It's real, but it comes with context that most headlines skip. In SURMOUNT-1, adults taking tirzepatide 15mg lost an average of around 20–21% of their body weight over 72 weeks, alongside a reduced-calorie diet and increased physical activity. Some analyses put the figure closer to 22.5%. Those numbers are striking, and they're why tirzepatide drew so much attention when it launched.

The catch is that trial participants had structured dietary support throughout. The averages also mask real spread: some people lost considerably more, others considerably less. Trials also exclude people with certain health conditions, so results in a broader population may differ. Citing the 20% figure as a personal forecast rather than a trial average is the error worth correcting early. Weight loss on any medicine is shaped by starting weight, adherence, lifestyle, and biology, not just which pen you use.

It's understandable to want certainty when you're thinking about a significant health decision. The evidence is genuinely strong; it just doesn't come with a guarantee attached, and any service that implies otherwise isn't being straight with you.

What SURMOUNT-1 actually measured, and why the design matters

SURMOUNT-1 enrolled 2,539 adults without type 2 diabetes, all with a BMI of 30 or above (or 27-plus with at least one weight-related condition). Participants were randomised to tirzepatide 5mg, 10mg or 15mg, or placebo, and followed for 72 weeks. The trial was double-blind and placebo-controlled, the gold-standard design for measuring a medicine's effect separately from lifestyle changes alone. Results were published in the New England Journal of Medicine, and NICE cited this data directly when appraising tirzepatide. You can read more about the broader evidence base on our tirzepatide trials overview.

Treatment started at 2.5mg (a dose chosen because it lets the body adjust before the therapeutic work begins) and was stepped up every four weeks by a prescriber. Participants at all three active doses lost significantly more weight than the placebo group. The dose-response relationship was clear: higher doses, on average, produced greater losses. That's why the titration schedule exists and why prescribers don't simply start everyone at the top.

A separate trial, SURMOUNT-2, looked at people with type 2 diabetes, where the results were still substantial but somewhat lower on average, because metabolic context affects the medicine's impact. If you want to compare results across different patient groups, our page on Mounjaro trials in the UK context covers that ground.

SURMOUNT-5: the head-to-head that drew the most attention

Until the SURMOUNT-5 trial, direct comparisons between tirzepatide and semaglutide 2.4mg (Wegovy) relied on indirect statistical modelling. The open-label trial, published in the New England Journal of Medicine in 2025, changed that. Over 72 weeks, 751 adults with obesity and no diabetes were randomised to one or the other. Tirzepatide produced greater average weight reduction than semaglutide 2.4mg.

That result matters because it's head-to-head data rather than cross-trial inference. It also comes with the usual caveats: the trial was open-label (participants knew which medicine they were taking), the doses compared were those medicines' standard maintenance doses, and individual responses still varied widely. For a fuller look at what those numbers mean side by side, the tirzepatide cardiovascular outcomes trial page explains the broader clinical programme beyond weight loss alone.

NICE referenced these comparisons in its appraisal of tirzepatide. The NICE technology appraisal TA1026, published in December 2024 and updated September 2025, recommended tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The SURMOUNT evidence was the clinical backbone of that recommendation.

What the trials don't tell you, and where a prescriber fits in

Clinical trials answer population-level questions. They can't tell you whether you as an individual will lose 10% or 22%, how your body will handle the side-effect profile, or whether your medical history changes the risk-benefit picture. The most common side effects across the SURMOUNT programme were gastrointestinal (nausea, loose stools, constipation, reflux) typically at their worst during the early weeks and after dose increases, then settling for most people. The NHS medicines page for tirzepatide lists these in full, and it's worth reading before you start.

The trials also used titration schedules managed by study clinicians. In practice, that means a prescriber reviews whether your dose is appropriate for you, it's not a self-directed process, and no credible service treats it as one. At nume, every consultation is read by a GPhC-registered Independent Prescriber, not automated software. For context on what the UK-specific access picture looks like, our tirzepatide CKD trial page covers one of the specialist evidence threads, while the tirzepatide trial UK page addresses how the trial population maps to UK-licensed eligibility criteria.

One practical question the trials can't answer is cost. If that's on your mind, our Mounjaro price comparison page walks through what UK private treatment typically includes and why the price-per-pen figure rarely tells the whole story.

If you've read the evidence and want to find out whether tirzepatide is clinically appropriate for you, the next step is straightforward: start your free consultation with our prescribers, and they'll assess your situation the same day.